Carla De Giovanni

Bologna, 40126, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy.

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy.

Journal: Cells
Published: June 07, 2021

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.

Journal: Oncogenesis
Published: March 31, 2021

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.

Journal: Scientific reports
Published: July 01, 2020

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Journal: Cancers
Published: October 23, 2019

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.

Journal: Cancers
Published: March 27, 2019

Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous.

Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous.

Journal: The Journal of nutritional biochemistry
Published: August 29, 2018

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

Journal: BMC cancer
Published: July 13, 2018

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Journal: Oncoimmunology
Published: February 05, 2018

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Journal: Oncotarget
Published: December 16, 2016

Genetic variation of a global germplasm collection of chickpea (Cicer arietinum L.) including Italian accessions at risk of genetic erosion.

Genetic variation of a global germplasm collection of chickpea (Cicer arietinum L.) including Italian accessions at risk of genetic erosion.

Journal: Physiology and molecular biology of plants : an international journal of functional plant biology
Published: July 19, 2016

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Journal: Breast cancer research : BCR
Published: August 09, 2014

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Journal: Oncotarget
Published: August 04, 2014
Showing 1-12 of 24

Last Updated: 09/26/2026